Lead Product(s) : Ecallantide
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ecallantide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hereditary Angioedema Types I and II.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 16, 2013
Lead Product(s) : Ecallantide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecallantide
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
Details : Ecallantide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Angioedemas, Hereditary.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 09, 2013
Lead Product(s) : Ecallantide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecallantide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ecallantide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Angioedema.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 28, 2011
Lead Product(s) : Ecallantide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecallantide
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema
Details : Ecallantide is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Angioedemas, Hereditary.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 03, 2010
Lead Product(s) : Ecallantide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
